TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04621500
Drug: cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled subjects will supplement with vitamin D3 at 4,000 IU daily for one year
Study: NCT04049110
Drug: Forxiga 10mg
Normalized name: Farxiga
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin 10mg per 24 hours, oral, for 7 consecutive days
Study: NCT00334282
Drug: Pazopanib
Normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral pazopanib tablet 800 mg once daily continuously
Study: NCT03759964
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1g of Ferric carboxymaltose diluted in 100 mL of IV isotonic serum saline at day 1 following surgery
Study: NCT01281228
Drug: exenatide
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The loading dose is 50 ng/min during 30 min, followed by a maintenance dose 20 ng/min for the rest of the tests.
Study: NCT01281228
Drug: exenatide + exendin (9-39)
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The loading dose is 50 ng/min during 30 min, followed by a maintenance dose 20 ng/min for the rest of the tests. Exendin 9-39 will be infused intravenously at doses of 600 pM/kg • min.
Study: NCT00162266
Drug: Abatacept (BMS-188667)
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV, 10 mg/Kg, monthly, for the duration of the trial
Study: NCT00162266
Drug: Abatacept (BMS-188667)
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous (IV) infusion, 2 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
Study: NCT00162266
Drug: Abatacept (BMS-188667)
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous (IV) infusion, 10 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
Study: NCT00764907
Drug: asparaginase
Normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV during reinduction
Study: NCT00764907
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV during reinduction
Study: NCT00764907
Drug: daunorubicin hydrochloride
Normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV during reinduction
Study: NCT00764907
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or orally during reinduction
Study: NCT00764907
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV during reinduction
Study: NCT00005614
Drug: Gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine via IV
Study: NCT00764907
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV during reinduction
Study: NCT00764907
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given intrathecally during reinduction
Study: NCT00764907
Drug: thioguanine
Normalized name: Thioguanine
DrugBank: Tioguanine (DB00352)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally during reinduction
Study: NCT00764907
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV during reinduction
Study: NCT00764907
Drug: vindesine
Normalized name: vindesine
DrugBank: Vindesine (DB00309)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV during reinduction
Study: NCT01896271
Drug: IL-2
Normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HD IL-2 (brand name Proleukin), 600,000 U/kg q8h X 14 dose, IV infusion
Study: NCT01735071
Drug: bevacizumab and trabectedin
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Arm A: bevacizumab (15 mg/kg) given as 1 hour infusion will be followed by trabectedin (1.1 mg/sqm) 3 hour iv infusion; to be repeated every 21 days until progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients
Study: NCT01735071
Drug: bevacizumab, trabectedin and carboplatin
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Arm B: cycle 1- 6, bevacizumab given as 1 hour infusion will be followed by carboplatin AUC 4 and trabectedin 3 hour iv infusion.~Cycle 7- end of treatment, bevacizumab given as 1 hour infusion will be followed by trabectedin 3 hour iv infusion.~Patient enrolled in arm B will receive (cycle 1-6): trabectedin 0.8 mg/m2 ,carboplatin AUC 4 day 1 every 28 days and bevacizumab 10 mg/kg iv on day 1 and day 15.~From cycle 7 to disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients will receive bevacizumab 15 mg/kg iv and trabectedin 1.1 mg/m2 day 1 every 21 days
Study: NCT02270827
Drug: Aminophylline
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous medication
Study: NCT00302133
Drug: Naltrexone hydrochloride
Normalized name: Naltrexone Hydrochloride
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone hydrochloride 50 mg capsule daily for 12 weeks
Study: NCT00620438
Drug: Lumefantrine-artemether and nevirapine
Normalized name: artemether and lumefantrine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of lumefantrine 480mg co-formulated with artemether 80mg twice daily for three days to HIV positive patients receiving nevirapine 200mg twice daily as part of their antiretroviral treatment
Study: NCT00620438
Drug: lumefantrine-artemether and efavirenz
Normalized name: artemether and lumefantrine
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of lumefantrine 480mg co-formulated with artemether 80mg twice daily for three days to HIV positive adults receiving efavirenz tablets 600mg once daily
Study: NCT00012558
Drug: lithium
Normalized name: Lithium
DrugBank: Lithium citrate (DB14507)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00012558
Drug: valproate
Normalized name: Valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00012558
Drug: bupropion
Normalized name: Bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00012558
Drug: paroxetine
Normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00012558
Drug: lamotrigine
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00012558
Drug: risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00012558
Drug: tranylcypromine
Normalized name: Tranylcypromine
DrugBank: Tranylcypromine (DB00752)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02098590
Drug: atovaquone/proguanil
Normalized name: ATOVAQUONE/PROGUANIL
DrugBank: Atovaquone (DB01117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants will be treated with atovaquone/proguanil when they develop a malaria infection or on day 28 after malaria challenge infection.
Study: NCT04336891
Drug: Moisturizer
Normalized name: MOISTURIZER
DrugBank: Oxybenzone (DB01428)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local non-hormonal moisturizers applied regularly every 2-3 days and lubricants as needed
Study: NCT03004066
Drug: Daptomycin
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: standard care
Study: NCT00357188
Drug: Atazanavir Sulphate + Ritonavir
Normalized name: atazanavir and ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Capsules, Oral, ATV 300 mg + RTV 100 mg, once daily, 10 days.
Study: NCT00357188
Drug: Atazanavir Sulphate + Ritonavir + Efavirenz
Normalized name: atazanavir and ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Capsules/Tablets, oral, ATV 400 mg + RTV 100 mg + EFV 600 mg, once daily, 14 days.
Study: NCT01749579
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 1 mg/kg bolus then 500 microg/kg every 2 minutes until sedation level equivalent to Ramsey 3
Study: NCT01749579
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam 0.03 mg/Kg stat and then the same dose repeated every 2 minutes until a sedation level of Ramsey 3 is achieved.
Study: NCT00161993
Drug: Gammagard S/D (Solvent/Detergent)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03408015
Drug: Lifitegrast
Normalized name: Lifitegrast
DrugBank: Lifitegrast (DB11611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lifitegrast ophthalmic solution, 5.0%. 1 drop instilled into each eye once in the morning and once before bed.
Study: NCT00275951
Drug: Cetuximab Plus P-HDFL
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab 400 mg/m2, IV, day 1 of cycle 1; then weekly IV 250 mg/m2. Cisplatin 24-hour IV infusion 35 mg/m2/day, plus HDFL (5-FU 2,000 mg/m2 and leucovorin 300 mg/m2), day 1 and day 8. HDFL IV, day 15.
Study: NCT03673163
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion of 2% lidocaine hydrochloride at 4 mL/h,prior to surgery and discontinued until 24 h after surgery.
Study: NCT03673163
Drug: Control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion of normal saline at 4 mL/h, prior to surgery and discontinued until 24 h after surgery.
Study: NCT03413059
Drug: Morphine Sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thoracic Epidural morphine
Study: NCT03413059
Drug: Triamcinolone Acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: thoracic epidural triamcinolone acetonide
Study: NCT03526419
Drug: Bupivacaine liposome
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: blood and milk samples will be obtained from those subjects after TAP block
Study: NCT01024712
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01024712
Drug: gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01024712
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02282956
Drug: Ropivacaine 0,75%
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ropivacaine injection
Study: NCT02282956
Drug: morphine and droperidol
Normalized name: Droperidol
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: i.v PCA
Study: NCT01538862
Drug: Granulocyte Colony Stimulating Factor (GCSF)
Normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: G-CSF 10mcg/kg/d SQ for 7 days
Study: NCT00199290
Drug: Trafermin (genetical recombination)
Normalized name: Burosumab (genetical recombination)
DrugBank: Trafermin (DB06244)
Approvals — FDA: no, EMA: no, PMDA: yes
Study: NCT00007527
Drug: naloxone
Normalized name: Naloxone
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01400516
Drug: Teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 20 μg, subcutaneous injection, 1 injection per day
Study: NCT01400516
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 IU of Vitamin D
Study: NCT01400516
Drug: TNF antagonist
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TNF antagonist as prescribed in clinical practice (such as etanercept or adalimumab)
Study: NCT00549562
Drug: Paliperidone ER
Normalized name: Paliperidone ER
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Starting dose is 3 mg per day. Can be titrated up to a maximum dose of 9 mg per day.
Study: NCT00663052
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ETN 50 mg QW + PBO QW for 12 weeks followed by ETN 50 mg QW for 12 weeks.
Study: NCT00663052
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ETN 50 mg BIW for 12 weeks folowed ETN 50 mg QW for 12 weeks.
Study: NCT03913091
Drug: Liposomal Bupivacaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal Bupivacaine Plus 0.5% Bupivacaine HCL
Study: NCT03913091
Drug: 0.5% Bupivacaine HCL
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5% Bupivacaine HCL for Interscalene Nerve Block (ISB)
Study: NCT02472938
Drug: dimethyl fumarate
Normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dimethyl fumarate 120 mg capsules
Study: NCT04067986
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab One course will last 28 days.Intravenous injection at a dose of 200 mg, q2w~One course will last 28 days. Oral administration at a dose of 250 mg/d
Study: NCT00918021
Drug: olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: normal dosage of olanzapine (the same dosage as on hospital ward)
Study: NCT00615056
Drug: Bevacizumab (avastin)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab intravenous \[IV\] infusion 5 mg/kg every two weeks until disease progression, intolerance or withdrawal of consent.
Study: NCT00615056
Drug: AG-013736 (axitinib)
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Axitinib is given at a starting dose of 5 mg twice daily \[BID\] continuous dosing until disease progression, intolerance or withdrawal of consent.
Study: NCT00586443
Drug: bevacizumab, everolimus, panitumumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cohort # subjects Bevacizumab Everolimus Panitumumab~* 3 3-6 5 mg/kg IV Q2 weeks 5 mg PO QoD 3.6 mg/kg IV Q2 weeks~* 2 3-6 5 mg/kg IV Q2 weeks 5 mg PO QoD 4.8 mg/kg IV Q2 weeks~* 1 3-6 10 mg/kg IV Q2 weeks 5 mg PO QD 4.8 mg/kg IV Q2 weeks~  1. 3-6 10 mg/kg IV Q2 weeks 10 mg PO QD 4.8 mg/kg IV Q2 weeks~ 2. 3-6 10 mg/kg IV Q2 weeks 10 mg PO QD 6 mg/kg IV Q2 weeks 3a 10 RPTD\* RPTD\* RPTD\* 3b 10 RPTD\*\* RPTD\*\* RPTD\*\*~     * Panitumumab and RAD001 started on Day 1, bevacizumab started on Day 15. \*\*Bevacizumab and RAD001 started on Day 1, panitumumab started on Day 15.
Study: NCT00615056
Drug: Bevacizumab (avastin)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab intravenous infusion \[IV\] 5 mg/kg every two weeks until disease progression, intolerance or withdrawal of consent.
Study: NCT00162565
Drug: beta-blocker treatment
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-blocker treatment
Study: NCT00084669
Drug: venlafaxine
Normalized name: Venlafaxine
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00084669
Drug: zolpidem tartrate
Normalized name: Zolpidem Tartrate
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03226340
Drug: S-amlodipine 2.5mg + Telmisartan 40mg
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will receive S-amlodipine 2.5mg + Telmisartan 40mg p.o. once a day for 12 weeks.
Study: NCT02023450
Drug: saquinavir and ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: micro and low dose
Study: NCT02023450
Drug: saquinavir and ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: standard dose
Study: NCT04067986
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib One course will last 28 days.Oral administration at a dose of 250 mg, qd
Study: NCT03733171
Drug: PLATELET RICH PLASMA
Normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP was injected in 1-2 ml by multiple injections into and circumferentially around the ulcer until bleeding stopped using a 25-G retractable, standard sclerotherapy needle
Study: NCT01940926
Drug: 68Ga-BNOTA-PRGD2
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose intravenous injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 at 30 minutes before PET/CT scanning
Study: NCT03302728
Drug: Lenalidomide 15mg
Normalized name: LENALIDOMIDE 15MG CAP,ORAL
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: At commencement of study : Lenalidomide will commence at 15 mg daily for days 1-14 of each cycle. Maximum number of cycles = 16. This is a dose finding study so doses will be adjusted depending on toxicity assessment over the course of the study. Dose may vary from 5 mg -25 mg daily depending on dose escalation results and recommendation of safety committee
Study: NCT03302728
Drug: Brentuximab Vedotin 1.8 mg/Kg
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: At commencement of study : Brentuximab vedotin 1.8mg/kg IV on day 1, repeated every 21 days. Maximum number of cycles = 16. This is a dose finding study so doses will be adjusted depending on toxicity assessment over the course of the study. Dose may be either 1.2 mg/Kg q21 days or 1.8 mg/kg q21 days depending on dose escalation results and recommendation of safety committee
Study: NCT03388190
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: FLOX: Intravenous oxaliplatin 85 mg/m2 on day 1; bolus 5-fluorouracil 500 mg/m2 and bolus Leucovorin on days 1 and 2; IV administration every 2 weeks.~Nivolumab: 240 mg flat dose; IV administration every 2 weeks.
Study: NCT03388190
Drug: FLOX
Normalized name: Floxin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FLOX: Intravenous oxaliplatin 85 mg/m2 on day 1; bolus 5-fluorouracil 500 mg/m2 and bolus Leucovorin on days 1 and 2; IV administration every 2 weeks.
Study: NCT01790490
Drug: Ketamine 0.41 mg/kg
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 52 minute iv infusion of ketamine 0.41 mg/kg
Study: NCT00584571
Drug: Escitalopram Therapy
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escitalopram; 10 mg every day, orally.
Study: NCT02675335
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02558790
Drug: L-Threonic Acid Magnesium Salt (L-TAMS)
Normalized name: threonic acid, L-
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00518908
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3.2 Vol % for postconditioning
Study: NCT02603809
Drug: Aprocitentan 5 mg
Normalized name: Aprocitentan
DrugBank: Aprocitentan (DB15059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule of 5 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.
Study: NCT02603809
Drug: Aprocitentan 10 mg
Normalized name: Aprocitentan
DrugBank: Aprocitentan (DB15059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two capsules of 5 mg aprocitentan, orally, once daily in the morning for 8 weeks.
Study: NCT02603809
Drug: Aprocitentan 25 mg
Normalized name: Aprocitentan
DrugBank: Aprocitentan (DB15059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule of 25 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.
Study: NCT02603809
Drug: Aprocitentan 50 mg
Normalized name: Aprocitentan
DrugBank: Aprocitentan (DB15059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule of 50 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.
Study: NCT02603809
Drug: Lisinopril 20 mg
Normalized name: lisinopril 20 MG
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One capsule of 20 mg lisinopril, orally, once daily in the morning for 8 weeks, along with placebo capsule matching aprocitentan
Study: NCT01790490
Drug: Ketamine 0.71 mg/kg
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 52 minute iv infusion of ketamine 0.71 mg/kg. This dose follows K1 in all 3 orderings.
Study: NCT03662984
Drug: Ciprofibrate 100Mg Tablet
Normalized name: ciprofibrate
DrugBank: Ciprofibrate (DB09064)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofibrate is a PPARα ligand and is considered to be a major regulator of the lipid metabolism. PPARα regulates the genes involved in mitochondrial function and fat metabolism and is therefore abundantly expressed in tissues that require high rates of FFA oxidation, like for instance in the heart and activation of PPARα in the heart may have beneficial effects on mitochondrial function and fat oxidative capacity.
Study: NCT05546255
Drug: Eribulin Mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The recommended dose of Eribulin is 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1
Study: NCT05546255
Drug: Lobaplatin
Normalized name: Lobaplatin
DrugBank: Lobaplatin (DB13049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The recommended dose of lobaplatin is 25mg/m2 administered intravenously over on Days 1
Study: NCT02759224
Drug: BRI-1501
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02759224
Drug: Irsogladine maleate
Normalized name: maleate
DrugBank: Irsogladine (DB13056)
Approvals — FDA: no, EMA: no, PMDA: no